Darwin Protocol

Darwin Protocol

TBA
788 Views
Darwin Protocol introduces the ability for individuals to trade, stake, and sell tokens free of charge. We have coined this Tokenomics 2.0, as we believe that it is the evolution of tokenomics. Darwin Protocol is an incorporated company in the United Kingdom, and creates many use cases for our tokens. The use cases are as follows: DarwinSwap, our DEX that allows us to do Tokenomics 2.0 (on our token and ANY other token) DarwinCommunity – our made-for-purpose DAO platform that controls the Darwin Protocol contract, LP, tokens collected from Tokenomics, and more.
4.6
TOTAL SCORE
3.5
ICO PROFILE

(weight: 45%)

1
TEAM PROOF

(weight: 20%)

Get widget
General
Website: Visit
White paper: Read
Dates: TBA
Token info
Ticker: DARWIN
Platform: Binance Chain
Kieran Murphy
TEAM LEAD
Participates in a number of projects
Matteo Cosenza
TECH LEAD
Participates in a number of projects
Bill Odida
SMART CONTRACT LEAD
Participates in a number of projects

Advisors (0)

HEIGHT - 0px
WIDTH - 0px
PUT THIS CODE TO YOUR WEBSITE
ICO List
Other Interesting ICOs
Upcoming
Universal Reward Protocol
By accepting to share their shopping data with the network, a shopper earns reward tokens, while the data is used by retailers to build redemption offers that best suit each customer’s needs. Shoppers can redeem their tokens through these exclusive and personalized offers.
Upcoming
DexBerry
DexBerry is a next-generation decentralized ecosystem Mega-Application backed by a revolutionary smart contract technology. The Mission of DexBerry is to leverage ever-evolving blockchain technologies to provide users with an application that supports easy access to cross-chain liquidity and tools for fast, easy, and secure acquisition of digital assets without moving from one project feature to another. With DexBerry, users can Analyze, Advertise, Acquire, Create, Compete, Earn, Game, Launch, Swap & more without moving 1 INCH.
Upcoming
Aimedis
Aimedis is an AI backed, blockchain and smart contract supported medical ecosystem, that changes the way patients, doctors, and hospitals communicate, connect and handle information. Using the Aimedis platform, users can store, secure and share their medical information only with the people they want to share it with by using the Aimedis right management system. Beside the records, AImedis offers videochat and communication with other patients and doctors, online prescriptions, online appointments, learning content, the inclusion of fitness trackers and devices like ECG or bloodpressure monitors into the system, while all transactions inside the system are backed by our porprietary private AIMChain blockchain, while the token is bound to a public blockchain (Aimedis dual-blockchain model). AIMSocial will be the new incentivised and decentralized medical social network where patients can help other patients and get rewarded for it, while the system is supported by AI.
Upcoming
Sponsy
Sponsy is disrupting the sponsorship industry. It is a one-stop online solution for sponsors and sponsees to conduct sponsorship deals. By tokenizing sponsorship assets and decentralizing decision-making, we do not only reduce costs, but also provide sponsees with a wider choice of sponsorship opportunities and make sponsorships available to every business.
Upcoming
Talao
Talao is the first Ethereum-based DAO for Talent, which introduces a unique way for users to own their data thanks to a secure digital vault storing their certificates on the blockchain. Talao provides a decentralized marketplace, governed by Talent, on which neither intermediaries nor commissions apply.
Upcoming
MediLOT
MediLOT is a health data protocol that aims to solve the concerns of Electronic Health Records (EHR). Current EHR systems are fragmented, centralised and lack patient ownership. Through a dual blockchain solution, MediLOT incorporates Artificial Intelligence capabilities onboard its control and data layers which allows the equitable sharing of health data. The MediLOT ecosystem will consist of patients, healthcare providers, researchers and commercial companies.